Management of Elevated Asymptomatic Tryptase

Diagnostic Approach

For a patient with elevated tryptase, the priority is diagnostic evaluation to determine the underlying cause, and preventive measures including an epinephrine auto-injector and avoidance of triggers, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2
Elevated tryptase itself does not cause symptoms; only active mast cell degranulation produces clinical manifestations, according to the European Academy of Allergy and Clinical Immunology 3
Confirmation that the measurement was taken during an asymptomatic period (not within 1-4 hours after acute symptoms) is crucial, as stated by the American College of Allergy, Asthma, and Immunology 1
Asymptomatic elevated tryptase never requires epinephrine or anaphylaxis emergency protocol, as per the guidelines from the World Allergy Organization 2

Tryptase level >20 ng/mL is a minor criterion for systemic mastocytosis and necessitates bone marrow evaluation, as recommended by the International Society for Stem Cell Research 1, 2
Tryptase level >200 ng/mL indicates high mast cell burden, suggesting advanced systemic mastocytosis or mast cell leukemia, according to the European Competence Network on Mastocytosis 1, 3
Diagnosis requires 1 major criterion + 1 minor criterion, or 3 minor criteria, as stated by the World Health Organization 1

An epinephrine auto-injector is prescribed for all patients with confirmed elevated tryptase, even if asymptomatic, as recommended by the American Academy of Pediatrics 1, 3, 2
Identification with a Medic Alert is necessary, as suggested by the American Medical Association 1
Education on avoiding triggers such as extreme temperatures, physical stimuli, alcohol, certain medications, stress, exercise, hormonal fluctuations, infections, and hot water is essential, according to the National Institute of Allergy and Infectious Diseases 4, 3

Antimediateur therapy, including antihistamines H1 and H2, leukotriene inhibitors, and cromolyn sodium, is used for symptomatic management of systemic mastocytosis or mast cell activation syndrome, as recommended by the European Academy of Allergy and Clinical Immunology 1, 2
These treatments are for symptom management, not for treating elevated tryptase itself, as stated by the American College of Allergy, Asthma, and Immunology 1, 2

Annual tryptase surveillance is recommended for patients with confirmed systemic mastocytosis to evaluate disease burden, as suggested by the International Society for Stem Cell Research 3
Multidisciplinary management involving allergy/immunology and hematology is necessary, according to the American Academy of Allergy, Asthma, and Immunology 3